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Abstract Anthrax is a severe bacterial infection that occurs
when Bacillus anthracis spores gain access into the body and
germinate in macrophages, causing septicemia and toxemia.
Anthrax toxin is a binary A^B toxin composed of protective
antigen (PA), lethal factor (LF), and edema factor (EF). PA
mediates the entry of either LF or EF into the cytosol of host
cells. LF is a zinc metalloprotease that inactivates mitogen-ac-
tivated protein kinase kinase inducing cell death, and EF is an
adenylyl cyclase impairing host defences. Inhibitors targeting
di¡erent steps of toxin activity have recently been developed.
Anthrax toxin has also been exploited as a therapeutic agent
against cancer.
' 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Horrendus magis est perimit qui corpora, carbo:
urit hic inclusus, vitalia rumpit apertus.2
Anthrax is an often fatal, rather uncommon, bacterial in-
fection caused by the rod-shaped Gram-positive bacterium
Bacillus anthracis. After entering into the body through skin
abrasions, inhalation or ingestion, B. anthracis spores are
phagocytosed by macrophages, which either remain in the
primary infection site or migrate to regional lymph nodes.
The spores germinate in the macrophages and become vege-
tative bacteria which lyse the macrophage, multiply in the
lymphatic system, and then enter the bloodstream, causing
massive septicemia and toxemia which has systemic e¡ects
that can lead to the death of the host. B. anthracis continues
its proliferation until the nutrients are terminated, triggering
sporulation which generates an immense number of highly
resistant spores. These are dispersed in the environment by
natural agents and remain intact for dozens, perhaps hun-
dreds of years, ready to infect animals and humans, restarting
the cycle of the pathogen [1^8].
Anthrax is an epizootic disease to which most mammals,
especially grazing herbivores, are considered susceptible. On
rare occasions, anthrax can be transmitted to humans, usually
through contact with infected animals or their products; there
are no known cases of human-to-human transmission. Cuta-
neous anthrax, the most common form of the disease, is easily
curable and usually heals spontaneously. However, a small
percentage of cutaneous infections becomes systemic and
these can be fatal. Cutaneous anthrax is initially characterized
by an edematous^necrotic lesion that evolves into a black
eschar. The color and the appearance of the black eschar
give the disease its name ‘anthrax’, which is derived from
the Greek word for coal. Systemic anthrax resulting from
the inhalation of the microorganism (inhalation anthrax) has
a mortality rate approaching 100%, with death usually occur-
ring rapidly after the onset of symptoms. Based on primate
data, the LD50 for humans (i.e. the dose su⁄cient to kill 50%
of the people exposed to it) is 3U103 to 5U104 inhaled
B. anthracis spores, varying in relation to the strain virulence
and the delivery system. The rate of mortality among persons
with infection resulting from ingestion of B. anthracis spores
(gastrointestinal and oropharyngeal anthrax) is variable, de-
pending on the outbreak. The involvement of meninges (an-
thrax meningitis) is a rare but almost always fatal complica-
tion of systemic anthrax. Whatever the portal of entry,
systemic anthrax involves massive bacteremia and toxemia
with unnoticed initial symptoms until the onset of hypoten-
sion, shock, and sudden death. Manifestations of the ad-
vanced disease, including shock and sudden death, are be-
lieved to result from the B. anthracis toxin action [1^8].
The major virulence factors of B. anthracis are the (exo)-
toxin that causes cell death and impairs host defences, and the
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capsule that inhibits the phagocytosis of vegetative bacilli. The
toxin-coding plasmid pXO1 carries the genes (cya, lef, and
pag) making up the secreted toxin, and the capsule-coding
plasmid pXO2 carries the genes (capB, capC, and capA) in-
volved in the synthesis of the poly-D-glutamyl capsule. The
expression of B. anthracis toxin and capsule genes is mediated
by the transcriptional activator AtxA, whose activity appears
to be a¡ected by host-speci¢c factors such as elevated temper-
ature (v 37‡C) and carbon dioxide concentration (v 5%) and
by the presence of serum components. The expression of the
capsule gene is also controlled by its own transcriptional reg-
ulator, AcpA [1^8].
2. The B. anthracis toxin
2.1. A tripartite lethal combination
The B. anthracis toxin belongs to the family of bacterial
binary A^B toxins characterized by an A moiety, which acts
within the cytosol of target cells and by a B moiety that binds
target cells and translocates the A moiety into the cytosol. It is
composed of a single B unit called protective antigen (PA), and
two alternative A subunits: the lethal factor (LF) or the edema
factor (EF). The three toxin components combine to form two
binary toxins, the lethal toxin (LT, i.e. LF+PA) and the edema
toxin (ET, i.e. EF+PA). PA binds directly to the so-called cell-
surface anthrax toxin receptor (ATR), a type I membrane pro-
tein with an extracellular Willebrand factor A-binding domain,
and so mediates the entry of LF and EF into the cytosol of host
cells. LF is a zinc-dependent endopeptidase which removes spe-
ci¢cally the N-terminal tail of mitogen-activated protein kinase
kinases (MAPKKs), leading to macrophage lysis. EF is a cal-
cium- and calmodulin- (CaM-) dependent adenylyl cyclase
which elevates the intracellular cAMP concentration, leading
to impairment of host defences [1^12].
2.2. The anthrax PA: toxin assembly and translocation
Anthrax PA, so-named for its use in vaccines, is the central
component of the tripartite protein toxin secreted by B. an-
thracis. PA mediates the entry of LF and EF into the host cell
(Fig. 1), but can also translocate chimeric proteins containing
PA-binding determinants, and is being evaluated for use as a
general protein delivery system, mainly for therapeutic pur-
poses [1^8,11,13,14].
Monomeric PA displays four structural domains, mostly
composed of antiparallel L-sheets. Domain 1 contains two
calcium ions and the cleavage site for activating proteases.
Domain 2 (i.e. pore formation) contains a large £exible loop
implicated in membrane insertion. The small domain 3 (i.e.
oligomerization) is involved in heptamer formation. Domain 4
(i.e. receptor binding) binds to ATR (Fig. 2) [5,15,16].
After binding ATR on the cell surface, PA is proteolytically
activated by a furin-like cell-surface membrane protease (Fig.
1). The enzymatic cleavage of PA occurs at a surface loop
within domain 1 (Fig. 2) with the release of the proteolytically
cleaved N-terminal fragment of PA (the PA20 fragment) in the
extracellular medium. PA20 plays no further role in anthrax
intoxication. Loss of PA20 leads the proteolytically cleaved
C-terminal fragment of PA (PA63) to self-associate, forming
symmetric, ring-shaped, membrane-inserting heptamers
([PA63]7) (Figs. 1 and 2). PA63 monomers pack like pie
wedges, with domains 1P (the remainder of domain 1) and 2
on the inside of the [PA63]7 ring and domains 3 and 4 on the
outside. [PA63]7 shows a negatively charged lumen, and ex-
poses a large hydrophobic surface for competitive binding of
the anthrax toxin enzymes LF or EF (Figs. 1 and 2) [15].
The LF and EF binding site was found to span the interface
between two adjacent PA63 subunits (Fig. 2), explaining the
dependence of LT and ET formation on PA oligomerization.
The location of residues comprising the LF and EF binding
site (Fig. 2) suggests that a single LF or EF molecule sterically
occludes two adjacent sites, consistent with the ¢nding that
[PA63]7 binds a maximum of three LF or EF molecules. The
resulting [PA63]7^LF and [PA63]7^EF complexes are taken up
into cells by ATR-mediated endocytosis and enter the lumen
of the acidic endosomal compartment (Fig. 1). Low pH trig-
gers a conformational change(s) of [PA63]7, leading to its in-
sertion into the membrane and the formation of a membrane-
spanning cation-selective channel, based on a 14-stranded
L-barrel (Fig. 1). This conversion drives the translocation of
LF and EF across the endosomal membrane into the cytosol
(Fig. 1) [4,5,7,10,15,17^20].
2.3. The anthrax LF: a zinc metalloprotease
Anthrax LF is a highly speci¢c, four-domain zinc metal-
loprotease that cleaves members of the MAPKK family with-
in their N-termini. This cleavage initiates a poorly character-
ized chain of events leading to host death (Fig. 1) [1^
8,11,21,22]. The correlation between MAPKK cleavage and
the reported LF-dependent inhibition of the release of pro-
in£ammatory mediators nitric oxide, tumor necrosis factor-K,
and interleukin-1L or macrophage cytotoxicity is the subject
of intensive investigations [1^8,23^26]. A rapid and selective
apoptosis of lipopolysaccharide-activated macrophages has
ATR
PA
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PA63
[PA63]7 EF/LF
ET/LT
MAPKKs
EF EF/LF LF
ATP
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Edema Cell death
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MAPKKs
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Fig. 1. Model of anthrax toxin action. PA secreted by B. anthracis
binds to ATR. Then, PA is cleaved by a furin-like cell-surface mem-
brane protease, releasing the PA20 subunit in the extracellular mi-
lieu. The remaining PA63 subunit oligomerizes to form [PA63]7 that
binds a maximum of three molecules of LF or EF. The assembled
toxins (ET and LT) are endocytosed and tra⁄cked to endosomes.
There the low pH triggers a conformational change(s) in [PA63]7
promoting the translocation of LF and EF across the membrane.
LF is a highly speci¢c zinc metalloprotease that cleaves members of
the MAPKK family within their N-termini. This cleavage initiates a
poorly characterized chain of events leading to the death of the
host. EF is a calcium- and CaM-dependent adenylyl cyclase that
causes an increase in intracellular cAMP concentration resulting in
water e¥ux and edema. Modi¢ed from [7] with permission of the
authors.
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been correlated to the LF-induced cleavage of the N-terminal
portion of MAPKKs with activation of the p38 mitogen-acti-
vated protein kinase (MAPK) [27]. By inducing apoptosis of
activated macrophages, LT could prevent the release of che-
mokines and cytokines that alert the immune system to the
presence of infecting B. anthracis, thereby facilitating the sys-
temic spread of the infection [27]. This result is di⁄cult to
reconcile with the previous, well documented, LT-induced cy-
totoxicity and with the fact that the ¢nal stages of anthrax
have all the characteristics of a septic shock triggered by an
extensive release of vasoactive mediators of in£ammation [1^
8,23^26]. Perhaps LF also cleaves other intracellular sub-
strates or it exhibits additional functions in host cells, which
could account for these pathophysiological observations [4].
The three-dimensional structure of LF reveals a protein
that has evolved through a process of gene duplication, mu-
tation and fusion, into an enzyme with high and unusual
speci¢city. LF comprises four domains, with the prevalence
of K-helices. Domain 1 (i.e. PA binding) binds the [PA63]7
component of LT. Domain 2 (i.e. VIP2-like) resembles the
ADP-ribosylating toxin VIP2 from Bacillus cereus, but the
active site has been mutated and recruited to participate in
substrate recognition. Domain 3 (i.e. helix bundle) is inserted
into domain 2, and seems to have arisen from a repeated
duplication of a structural element of domain 2. Domain 4
(i.e. catalytic center) is distantly related to the zinc metallo-
protease family and contains the active site (Fig. 2) [28].
The active site zinc ion is coordinated tetrahedrally to the
LF domain 4 by a water molecule and three side chains (i.e.
His686, His690, and Glu735), in a structural arrangement
typical of the thermolysin family. Glu687 acts as a general
base to activate the zinc-bound water molecule during catal-
ysis and Tyr728 (located on the opposite side of Glu687)
probably functions as a general acid to protonate the leaving
amino group [28].
The LF broad deep groove holding the substrate (V40 AT
long) is contiguous with the active site center (Fig. 2). The
groove has an overall negative electrostatic potential contain-
ing clusters of Glu/Asp as well as Gln/Asn residues. The align-
ment of the N-terminal region of MAPKKs made it possible
to determine a consensus motif for the cleavage site: positively
charged residues are located at positions P7^P4 and hydro-
phobic residues at P2 and P1P. It is worth noting that the
EF:MAPKK-2 substrate adduct (Fig. 2) is the ¢rst example
of a protease in complex with its uncleaved substrate and
might represent a ‘pre-cleavage’ adduct [28,29].
2.4. The anthrax EF: a calcium- and CaM-activated adenylyl
cyclase
Anthrax EF is a calcium- and CaM-dependent adenylyl
cyclase that takes ATP, clips o¡ two phosphates and forms
cAMP. EF £oods the cell with cAMP, upsetting water homeo-
stasis and destroying the delicate balance of intracellular sig-
naling pathways. Moreover, EF impairs neutrophil function(s)
and it is believed to be responsible for the edema found in
cutaneous anthrax (Fig. 1) [1^8,11].
The C-terminal catalytic portion of EF (i.e. EF58) shares no
signi¢cant structural homology with mammalian adenylyl cy-
clases or any other protein. EF58 comprises three globular
domains (i.e. 1 or CA, 2 or CB, and 3 or helical) and three
switch loops (i.e. A, B and C) (Fig. 2). Domain 1 binds the
[PA63]7 component of ET. Remarkably, EF58 and LF share
MONOMERIC PROTECTIVE ANTIGEN
HEPTAMERIC PROTECTIVE ANTIGEN
LETHAL FACTOR
EDEMA FACTOR
Fig. 2. Crystal structures of the anthrax toxin components PA63
[15], [PA63]7 [7], LF [28], and activated EF58 [30]. Critical residues
of [PA63]7 involved in binding to LF and EF lie at the interface be-
tween two adjacent PA63 monomers. Residues Arg178, Lys197,
Arg200, Ile207, Ile210, and Lys214, when mutated, prevent LF
binding. PA63 monomers are colored gray and green for easier rec-
ognition of individual subunits. The black arrow indicates the pro-
teolytic cleavage site of PA resulting in PA63 generation. Red, black,
and light blue spheres indicate calcium, zinc and metal ions, respec-
tively. PA63, LF, and activated EF58 were drawn with MOLSCRIPT
[48]. For further structural details on individual protein regions, see
[7,15,28,30]. The crystal structure of [PA63]7 was reproduced from
[7] with permission of the authors.
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signi¢cant homology at the level of domain 1, competing for
the same binding site on [PA63]7 (Figs. 1 and 2) [5,7,17^20].
The EF58 active site lies at the interface of domains 1 and 2,
which together constitute the catalytic core (Fig. 2) [30].
The structure of EF58 alone di¡ers signi¢cantly from that of
calcium- and CaM-activated EF58, but there are essentially no
di¡erences between the structures of EF58^CaM with and
without the non-cyclizable substrate analog 3P-deoxy-ATP.
CaM occupies much of the same volume taken by domain 3
in the structure of EF58 alone. To accommodate CaM, the
EF58 domain 3 undergoes V15 AT translation and V30‡ ro-
tation away from the EF58 catalytic core, such that domains 1
and 3 and the switch loop C (composed of residues from the
linker that connects domains 1 and 3) form a large clamp that
almost completely encircles CaM (Fig. 2). In addition to the
domain 3 displacement, the three switch loops A, B and C
undergo large conformational changes in response to CaM
binding, leading to EF58 activation and permitting substrate
binding. CaM bound to EF58 shows an extended conforma-
tion (Fig. 2), very di¡erent from the collapsed geometry ob-
served in other structures of CaM bound to e¡ector peptides
[30].
The location of 3P-deoxy-ATP and of the single metal ion in
the catalytic site of activated EF58^CaM (Fig. 2) is in keeping
with a mechanism centered on residue His351 acting as the
catalytic base. Such a mechanism di¡ers from that proposed
for mammalian adenylyl cyclases which are thought to require
two metal ions [30].
3. Fight against anthrax
B. anthracis strains are generally sensitive to a variety of
antibiotics, including penicillin, doxicyclin, and £uoroquino-
lones. However, the paucity of early symptoms and the rapid
course of the disease make the antimicrobial therapy ine¡ec-
tive, especially in the case of inhalation anthrax, calling for
alternative therapeutic strategies [1^8,31,32].
Vaccination has protected cattle and select humans (e.g. the
military personnel) by eliciting a strong humoral response
primarily directed to the neutralization of PA activity, but it
is not recommended for population-wide prophylaxis [1^8,32^
38]. Animal studies also indicate that passive immunization
with monoclonal antibodies against PA provides some protec-
tion to the lethal challenge with B. anthracis [39,40].
At present, pharmacological inhibition of toxin activity
seems to be the major (if not the only) therapeutic option
for severely ill patients, especially in the unlucky eventuality
of a bioterroristic attack involving inhalation anthrax
[4,32,41,42]. Notably, a soluble extracellular ATR domain
comprising the PA binding site prevents PA binding to
ATR and protects cultured cells from toxin action [9]. Fur-
thermore, a peptide that binds [PA63]7 and inhibits the inter-
action with LF (i.e. impairs LT assembly) protects rats from
LF-induced death [43]. Accordingly, the mutation of LF res-
idues involved in the interaction with PA abrogates LT as-
sembly and intoxication [17]. Rats and cultured cells chal-
lenged with LT are also protected by mutated PA63 that
binds cells, co-oligomerizes with wild-type PA63 and binds
LF, but is unable to form channels and translocate LF into
the cytosol. A single mutated PA63 monomer per heterohep-
tamer is su⁄cient to abolish LF translocation [33,34]. The
inhibition of the LF catalytic activity is an additional step
of anthrax toxin therapy; peptides impairing LF activity
were recently found to abrogate LF cytotoxicity in a macro-
phage cell line [44]. Finally, protection from LT might be
achieved by interfering with the function(s) of Kif1C, a kine-
sin-like motor protein which mediates mouse macrophage re-
sistance to LF [4,45]. The redundancy of this microtubule-
based molecular motor protein in mammals [46] may be of
advantage as a therapeutic approach.
4. The therapeutic use of the anthrax toxin
Since MAPKKs regulate MAPKs, the discovery that LF
cleaves MAPKKs hinted that LT could be used as a thera-
peutic against cancer cells in which MAPKs are activated by
oncogenic proteins such as Ras. In fact, intratumorally in-
jected LT has been shown to inhibit the growth of Ras-trans-
formed cells implanted in athymic nude mice, with no appar-
ent systemic toxicity. Moreover, LT greatly reduces tumor
neovascularization, a critical step in tumor growth and spread
[47]. Furthermore, mutated PA molecules were engineered by
replacing the furin site with recognition sites for matrix metal-
loproteases and urokinase plasminogen activator, which are
overexpressed in a variety of tumor tissues and cell lines.
Consequently, only tumor cells overexpressing these proteases
could activate PA mutated at the furin site. The engineered
PA directs toxicity towards tumor cells without a¡ecting non-
transformed cell lines [13,14]. Future design of such therapeu-
tic agents will take advantage of both the unique properties
exhibited by cancer cells and the powerful catalytic activity of
LF and EF. These features ensure selective damage of tumors
even at very low dosage, thereby improving the therapeutic
index of these drugs.
There is some good in every ill.
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